Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai has rolled out its breast cancer drug Halaven - a non-taxane, microtubule dynamics inhibitor that belongs to a class of antineoplastic agents, the halichondrins, in Japan.
Subscribe to our email newsletter
The US Food and Drug Administration approved Halaven is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease.
Halaven has demonstrated overall survival benefit in pretreated metastatic breast cancer by 2.7 months compared to treatment of physician’s choice (TPC), in a Phase III study (EMBRACE).
Eisai also intends to develop Halaven for the treatment of other types of cancer such as non-small cell lung cancer, sarcoma, and prostate cancer.